BofA Raises PT on Jazz Pharmaceuticals (JAZZ) to $225 From $217

Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the most promising future stocks according to Wall Street analysts. On August 14, BofA raised the firm’s price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) to $225 from $217, keeping a Buy rating on the shares.

Jazz Pharmaceuticals plc (JAZZ): Among Billionaire Ray Dalio’s Bridgewater’s Stock Picks with Huge Upside Potential

A biopharmaceutical scientist in their lab, studying a newly-diagnosed therapy-related acute myeloid leukemia. .

The firm told investors in a research note that it spoke with two key opinion leaders after the recent approval of Modeyso to treat an ultra-rare brain tumor. The leaders offered “positive feedback” on Modeyso uptake along with the odds of success for the confirmatory Phase 3 study.

The firm added that while the lead US indication for Modeyso for the recurrent setting is likely to be niche, the call from the experts left it “more assured” about the potential of the confirmatory ACTION trial, which may bolster peak US sales to greater than $400 million.

Jazz Pharmaceuticals (NASDAQ:JAZZ) develops medicines for serious diseases. Its primary marketed products include Xywav, Xyrem oral solution, Epidiolex oral solution, Rylaze, Zepzelca, Defitelio, and Vyxeos liposome for injection.

These medicines treat excess daytime sleepiness (EDS) in narcolepsy patients seven years of age or older, tepatic veno-occlusive disease (VOD), and other ailments.

While we acknowledge the potential of JAZZ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JAZZ and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.